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Objective: Metabolic syndrome is defined by the clustering in the same person of at least three risk factors such as
hyperglycemia, hypertriglyceridemia, low levels of high-density lipoprotein, hypertension, and abdominal obesity. In
patients with peripheral arterial disease (PAD), we investigated the prevalence of metabolic syndrome and its relationship
with the severity of peripheral circulatory insufficiency, inflammatory status, and cardiovascular comorbidity.
Methods: The presence of metabolic syndrome was assessed in 154 consecutive PAD patients (115 men, 39 women).
Inflammatory status was assessed by measuring serum levels of C-reactive protein (CRP).
Results: Metabolic syndrome was present in 51.9% (42.7 % in men, 74.3% in women, P < .01). Patients with an
ankle/brachial index (ABI) <0.64 (median) were more likely to have metabolic syndrome than those with less severe
PAD (63.9% vs 42.8%, P < .02). The association between a low ABI and metabolic syndrome was maintained after
adjustment for age and sex (odds ratio [OR], 2.19; 95% confidence interval [CI], 1.03 to 4.68). Compared with PAD
patients without metabolic syndrome, those with the syndrome had greater body mass index (28.2 [25.6; 29.8] kg/m2
vs 26.1 [24.2; 27.7] kg/m2, P < .01) and higher levels of CRP (3.9 [1.6; 7.6] mg/L vs 2.0 [1.1; 3.7] mg/L, P < .02).
A previous myocardial infarction was documented in 58.2% of patients with and in 37.5% of those without metabolic
syndrome (P < .01). At multivariate analysis, metabolic syndrome was significantly associated with previous myocardial
infarction also after adjustment for ABI (OR, 2.15; 95% CI, 1.06 to 4.38).
Conclusions: Metabolic syndrome is present in >50% of PAD patients. The finding that well-established indicators of
increased cardiovascular risk such as low ABI and increased CRP levels cluster with metabolic syndrome suggests that
identification of this syndrome in these high-risk patients could indicate an even greater risk of cardiovascular events.
(J Vasc Surg 2006;44:101-7.)Metabolic syndrome, which is defined by the clustering
in the same person of at least three risk factors such as
hyperglycemia, hypertriglyceridemia, low levels of high-
density lipoprotein (HDL), hypertension, and abdominal
obesity1 confers an increased risk for coronary artery disease
(CAD).2-4 It is a widely shared belief that metabolic syn-
drome is a growing and pressing problem for society.
Indeed, this condition is present in 9% to 22% of healthy
subjects,2,4,5 and its prevalence increases in high-risk pop-
ulations.6,7 In particular, a recent article reports that in
patients with peripheral arterial disease (PAD), the preva-
lence of metabolic syndrome is as high as 58%, greater than
that observed in subjects with coronary and cerebrovascular
disease.6 This finding may have relevant clinical implica-
tions, considering that PAD is highly prevalent in the adult
populations,8,9 is associated with elevated cardiovascular
comorbidity,10 and portends worse outcome.11-13
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doi:10.1016/j.jvs.2006.02.048Unfortunately, however, little is known about the rela-
tionship between metabolic syndrome and the clinical cor-
relates of PAD. Accordingly, in a group of patients with
PAD, we investigated the association of metabolic syn-
drome with (1) severity of atherosclerotic disease in the
lower limbs, (2) risk factors not included in the definition of
metabolic syndrome, and (3) cardiovascular comorbidity.
The answers to these questions may help to clarify the
mechanisms that favor the progression of the atheroscle-
rotic disease in a population at high risk.
METHODS
Between July 2004 and October 2005, 154 consecu-
tive patients (115 men, 39 women) entered the study with
a qualifying diagnosis of PAD, defined as an ankle/brachial
index (ABI) of 0.90 and, in diabetic patients with ABI
0.90, a history of typical claudication associated with one
or more stenosis 50% of a lower-extremity artery. Of
these, 142 were affected by intermittent claudication, and
12 had critical limb ischemia (pain at rest, or trophic lesions
in the affected limb, or both). All participants gave their
written informed consent to be in the study, which was
approved by our institutional ethics committee.
Data collection. Historical and demographic infor-
mation was collected at the first visit, after which all patients
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cording to the routine protocol of our vascular laboratory.
In brief, systolic pressure in the right and left posterior tibial
arteries and the right brachial artery was measured twice
with an echo color Doppler ultrasound scanning probe
after the patients had been resting supine for 5 minutes.
The average of the two measurements was used to evaluate
ABI. The lower ABI value of the two legs was used for
statistical analyses. Then, all patients underwent echo color
Doppler ultrasound scanning of the abdominal aorta, the
lower limbs, and the carotid arteries. Patients with no
history of CAD underwent dipyridamole myocardial perfu-
sion imaging to verify the presence or absence of ischemic
heart disease.
Fasting venous blood was obtained with a nontrau-
matic venipuncture. Serum C-reactive protein (CRP) was
determined with highly sensitive (hs) assay (Dade Behring
Diagnostics, Marburg, Germany). Serum concentrations of
triglycerides, total cholesterol, HDL cholesterol, low-den-
sity lipoprotein (LDL) cholesterol, and fasting glucose
were measured with commercially available kits.
Diagnostic criteria. Metabolic syndrome was diag-
nosed according to the Adult Treatment Panel III (ATP
III) criteria,1 including three or more of the following
abnormalities: abdominal obesity (waist circumference
102 cm in men;88 cm in women), high blood pressure
(130 mm Hg systolic or 85 mm Hg diastolic), hyper-
triglyceridemia (serum triglycerides 150 mg/dL), low
levels of serum HDL cholesterol (40 mg/dL in men;
50 mg/dL in women), and high fasting glucose (110
mg/dL). Patients taking glucose-lowering agents or anti-
hypertensive drugs were considered as having high fasting
glucose and high blood pressure, respectively.
A history of cardiovascular disease was confirmed with
hospital records documenting CAD (previous myocardial
infarction, or positive coronary angiogram, or positive
myocardial scintigram) and carotid vessel disease (previous
stroke or ultrasonography-proved stenosis50% in at least
one carotid artery). Infrarenal abdominal aortic aneurysm
(AAA) was defined by a lumen vessel dilation of 3 cm at
Table I. Peripheral arterial disease severity, body mass ind
prevalence of previous myocardial infarction in patient gro
Group A
(n  59)
Group B
(n  16)
Group C
(n  21)
ABI 0.64 (%) 21 (35.5) 8 (50.0)
Bilateral PAD (%) 36 (61.0) 12 (75.0)
BMI (kg/m2) 26.5 (24.2-27.9) 25.3 (23.7-2
Obesity (%) 5 (8.5) 1 (6.2)
hs-CRP (mg/L) 2.2 (1.4-5.4) 1.9 (0.8-2.8)
Previous MI (%) 23 (38.9) 5 (31.2)
ABI, Ankle brachial index; PAD, peripheral arterial disease; BMI, body mass
not significant.
Data are presented as medians (interquartile ranges) and numbers (percent
*Group A, no diabetes and no metabolic syndrome; group B; patients with
and no diabetes; group D, patients with both metabolic syndrome and diabthe echo color Doppler ultrasound scanning.Statistical analysis. Data are expressed as mean 
standard deviation (normally distributed) or median plus
25th and 75th percentile (nonnormally distributed). Dif-
ferences between patients with and without metabolic syn-
drome were tested with unpaired t test (normally distrib-
uted), Mann-WhitneyU test (nonnormally distributed), or
2 test (categoric variables).
For BMI and hs-CRP, which were nonnormally distrib-
uted, the comparison between patients with fewer than
three components of the metabolic syndrome, those with
three, and those with four components were made by
Kruskal-Wallis test. Multivariate logistic regression analysis
was used to assess the association between metabolic syn-
drome and other variables.
To verify whether diabetes alone was responsible for
metabolic syndrome observations, we divided the study
population into four groups: group A, patients with no
metabolic syndrome and no diabetes; group B, patients
with diabetes and no metabolic syndrome; group C,
patients with metabolic syndrome and no diabetes; and
group D, patients with both metabolic syndrome and
diabetes. Group comparisons were made by Kruskal-
Wallis test for BMI and CRP, and 2 test was used for
categoric variables.
RESULTS
PAD severity and metabolic syndrome. Metabolic
syndrome was present in 79 (51.9%) of 154 PAD patients
included in this study, the prevalence being greater in
women than in men (74.3% vs 42.7%, P  .01). In the 81
patients with an ABI0.64 (median), the prevalence of the
syndrome was significantly higher than in the 73 with an
ABI 0.64 (63.9% vs 42.8%, P  .016). The association
between low ABI and metabolic syndrome was also main-
tained after adjustment for age and sex (odds ratio [OR],
2.19; 95% confidence intervals [CI], 1.03 to 4.68; P 
.05). These results remained substantially unmodified
when four diabetic patients with abnormally elevated ABI
were excluded from the analyses. As summarized in Table I,
when patients were divided into the four groups, a signifi-
lasma levels of highly sensitive C-reactive protein, and
Group D
(n  58) P
9 (42.8) 43 (74.1) .008
14 (66.7) 43 (74.1) NS
27.0 (25.1-29.5) 29.0 (25.9-30.0) .002
3 (14.3) 15 (25.9) .025
3.4 (1.4-8.8) 4.0 (2.0-7.6) .023
10 (47.6) 36 (62.1) .061
; hs-CRP, highly sensitive C-reactive protein;MI,myocardial infarction;NS,
es and no metabolic syndrome; group C, patients with metabolic syndromeex, p
ups*
6.8)
index
age).cant difference was observed with respect to the prevalence
75th
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bilateral PAD was not associated with the metabolic syn-
drome, the prevalence of which was similar in the four
groups.
The presence of critical limb ischemia was not associ-
ated with a higher prevalence of metabolic syndrome,
which was present in six of the 12 critical limb ischemia
patients. Only one patient with diabetes and not metabolic
syndrome presented critical limb ischemia.
Cardiovascular risk factors and metabolic
syndrome. The number of patients with none, one, two,
three, four, or five components of the metabolic syn-
Table II. Baseline characteristics of the study population
Yes (n 
Cardiovascular risk factors not
included in the metabolic syndrome
Age (yr) 67.1  9
Male/female 50/29
Total cholesterol (mg/dL) 196  44
LDL cholesterol (mg/dL) 119  31
Never smokers (%) 17 (21.5)
Ex smokers (%) 33 (41.8)
Current smokers (%) 29 (36.7)
BMI (kg/m2) 28.2 (25.6
BMI 30 kg/m2 (%) 18 (22.8)
CRP (mg/L) 3.9 (1.6; 7
Components of metabolic syndrome
High fasting glucose (%) 63 (79.7)
Glycemia (mg/dL) 147  57
Hypertension (%) 79 (100)
SBP (mm Hg) 140  22
DBP (mm Hg) 80  16
Hypertriglyceridemia (%) 52 (65.8)
Triglycerides (mmol/L) 182  80
Low HDL cholesterol (%) 48 (60.7)
HDL cholesterol (mmol/L) 43  13
Abdominal obesity (%) 63 (79.7)
Waist circumference (cm) 103  10
HDL, High-density lipoprotein; LDL, low-density lipoprotein; BMI, body
blood pressure.
Unless otherwise indicated, data are means  SD, or median and 25th and
Table III. Treatments in patients with and without metab
Yes (n  79) (%)
Oral hypoglycemic drugs 15 (18.9)
Insulin 14 (17.7)
DM patients treated only
with hypoglycemic diet
6 (7.6)
Statins 58 (73.4)
Other hypolipemic drugs 23 (29.1)
-Blockers 27 (34.2)
Calcium antagonists 28 (35.4)
ACE inhibitors 58 (73.4)
DM, diabetes mellitus; ACE, angiotensin-converting enzyme inhibitor.drome was 7 (4.5%), 45 (29.2), 23(14.9), 55 (37.7%),23 (14.9%), and 1 (0.6%), respectively. Tables II and III
summarize, respectively, the characteristics and treat-
ments of the study population according to the presence
or absence of the metabolic syndrome.
Hypertension was present in all patients with the
syndrome, and hyperglycemia and abdominal obesity
were also highly prevalent (79.7% for both). With respect
to risk factors not included in the definition of metabolic
syndrome, no group difference was observed for age and
smoking habit. Conversely, patients with metabolic syn-
drome had a greater BMI (28.2 [25.6; 29.8] kg/m2 vs
26.1 [24.8; 27.7] kg/m2, P  .01), and consequently, a
Metabolic syndrome
PNo (n  75)
67.5  10 .774
65/10 .001
190  38 .332
121  39 .756
10 (13.3) .174
37 (49.3) .292
28 (37.3) .994
8) 26.1 (24.8; 27.7) .01
6 (8.0) .01
2.0 (1.1; 3.7) .015
16 (21.3) .001
103  33 .001
61 (81.3) .001
137  23 .293
75  12 .074
3 (4.0) .001
108  28 .001
4 (5.7) .001
55  15 .001
14 (18.7) .001
95  7 .001
dex; CRP, C-reactive protein; SBP, systolic blood pressure; DBP, diastolic
percentile.
syndrome at the study entry
tabolic syndrome
PNo (n  75) (%)
8 (10.6) .019
3 (4.0) .001
3 (4.0) .141
40 (53.3) .01
5 (6.7) .001
19 (25.3) .231
34 (45.3) .211
42 (56.0) .02479)
; 29.
.6)
mass inolic
Megreater prevalence of obesity. Actually, a BMI 30
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of those without the syndrome (P  .01). Table 1 lists
BMI values and prevalence of obesity in the groups A, B,
C, and D. It is noteworthy that patients with both
metabolic syndrome and diabetes had a significantly
higher BMI than those with diabetes without metabolic
syndrome (P  .002).
Metabolic syndrome was associated with a more
pronounced inflammatory profile, serum levels of CRP
being 3.9 (1.6; 7.6) mg/L in patients with the syndrome
and 2.0 (1.1; 3.7) mg/L (P  .015) in those without
(Table II). Statin use was not associated with reduced
levels of CRP in patients with and without metabolic
syndrome. Actually, among patients with metabolic syn-
drome, CRP levels were 3.9 (1.8; 7.3) mg/L in those
taking statins and 3.8 (1.8; 7.9) mg/L in those without
statin treatment. The corresponding values for patients
without metabolic syndrome were 1.7 (1.0; 3.2) mg/L
and 2.1 (1.2; 4.8) mg/L. Interestingly, patients with
both diabetes and metabolic syndrome had higher CRP
levels than those with diabetes and no metabolic syn-
drome (P  .023) (Table I).
Another interesting finding is that both BMI and CRP
showed a significant progressive increase with the increase
in the number of the components of the metabolic syn-
drome (Fig). The only patient with all five of the metabolic
syndrome components was excluded from this analysis.
Cardiovascular comorbidity and metabolic
syndrome. Among PAD patients with metabolic syn-
drome, a previous myocardial infarction was documented
in 46 (58.2%) but was only found in 28 (37.3%) of those
without the syndrome (P  .01). Table IV shows crude and
adjusted odds ratios for the association of previous myocar-
dial infarction with the metabolic syndrome and any of its
components. At the univariate analysis, previous myocar-
dial infarction was significantly associated with metabolic
syndrome (P  .008), low levels of HDL cholesterol (P 
.042), and high fasting glucose (P  .036). After adjust-
ment for age and sex (model I), metabolic syndrome and
high fasting glucose maintained a significant association
with myocardial infarction (P  .011, and P  .029,
respectively), and low HDL cholesterol approached the
Fig. Body mass index (BMI) and serum levels of C-reactive pro-
tein (CRP) according to the number of components of the meta-
bolic syndrome.statistical significance (P .051). After adjustment for ABI(model II), only the metabolic syndrome was significantly
associated with previous myocardial infarction (P  .034).
Table I shows that the differences in the prevalence of
previous myocardial infarction between the groups A, B, C,
D approached statistical significance (P .061). However,
patients with metabolic syndrome and diabetes showed a
greater prevalence of previous myocardial infarction than
those with diabetes alone (P  .039).
No association was found between the metabolic syn-
drome and previous stroke, three of which had occurred in
patients with the syndrome and four in those without.
Among the 79 patients with metabolic syndrome, no dif-
ference in the prevalence of both myocardial infarction and
stroke was found between those with three and those with
four components of the syndrome. No significant differ-
ence in the prevalence of carotid stenosis 50% and AAA
was observed between patients with and without metabolic
syndrome (data not shown).
DISCUSSION
Results of the present study confirm the observation
that in PAD, metabolic syndrome is highly prevalent6 and
extend the previous findings showing that in these patients,
metabolic syndrome is strongly associated with increased
levels of CRP, increased BMI, and increased prevalence of
previous myocardial infarction.
In the Second Manifestation of Arterial Disease
(SMART) study, Gorter et al6 found that the metabolic
syndrome was present in 58% of PAD patients, with
women showing a higher prevalence than men (65% vs
55%). These figures are quite similar to those observed in
the present study, which also shared with the SMART
study the finding that high blood pressure was the com-
ponent of the metabolic syndrome more often observed
in PAD. However, different from that study in which
hypertension was followed by low HDL-cholesterol and
hypertriglyceridemia, we found that high fasting glucose
was the second most prevalent component of the meta-
bolic syndrome in our PAD population. This difference
may be important, because insulin resistance is regarded
as the primary etiologic process of the metabolic syn-
drome.14,15
We found also that the prevalence of this syndrome
was greater in PAD patients with ABI 0.64 (median)
than in those with less compromised peripheral circula-
tion. Consistently, in the SMART study,16 the metabolic
syndrome was associated with lower ABI, although this
finding was observed not in PAD patients but in subjects
with manifest atherosclerotic disease of other vascular
beds. In PAD, a reduced ABI is the most powerful
negative prognostic indicator, and thus, the observation
that it clusters with the metabolic syndrome could imply
an even greater risk of future cardiovascular events. We
did not find any difference in the prevalence of metabolic
syndrome between patients with and without critical
limb ischemia; however, this finding may be biased by
the low number of 12 patients with critical limb ischemia
in our series.
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independent risk factor for PAD development and sever-
ity19,20 and predicts future cardiovascular events in pa-
tients with severe intermittent claudication or critical
limb ischemia.20,21 Furthermore, a recent study22 re-
ports that elevated CRP levels increase the likelihood of
PAD in adults with metabolic syndrome. In the SMART
study,6,16 CRP levels were not assessed, and thus, we
believe our data are the first to show a strong association
between elevated CRP levels and metabolic syndrome in
PAD. We found that the number of components of the
metabolic syndrome was significantly associated with
increased levels of CRP.
A similar trend in the general population was observed
by others4,23 and probably reflects the fact that elevated
CRP levels are associated with many of the components of
the metabolic syndrome.24-26 Three large population stud-
ies examined the relationship between CRP, metabolic
syndrome, and incident cardiovascular events.4,27,28 In all
three, CRP and metabolic syndrome were both indepen-
dent predictors of events. Furthermore, in subjects with
high CRP levels, the relative risk of events virtually doubled
that found with either parameter alone.4
At the present, no study has investigated the predic-
tive value of metabolic syndrome in PAD. Future pro-
spective studies will clarify whether the presence of the
syndrome in these patients adds to the prognostic value
provided by ABI and CRP. BMI, which we found in-
creased in patients with metabolic syndrome, also pre-
dicts cardiovascular risk,29,30 but its prognostic role in
PAD is unknown.
A number of studies have shown that the individual
risk factors comprising the metabolic syndrome each
carry a different odds ratio for predicting prevalent or
incident CAD.4,31,32 In our population of PAD patients,
we found that at the univariate analysis, diabetes melli-
tus, low HDL, and metabolic syndrome were signifi-
cantly associated with the presence of coexistent CAD,
but no relationship was found for hypertriglyceridemia
and abdominal obesity. After adjustment for age and sex,
Table IV. Crude and adjusted odds ratios for the associat
syndrome and any of its components
Univariate analysis
OR 95% CI P
Metabolic syndrome 2.41 1.26-4.62 .008
High fasting glucose 1.76 1.04-2.99 .036
Hypertension 1.2 0.48-3.01 .7
Hypertriglyceridemia 1.24 0.68-2.23 .484
Low HDL cholesterol 1.99 1.03-3.85 .042
Abdominal obesity 1.05 0.45-2.47 .906
OR, Odds ratio; CI, confidence intervals; HDL, high-density lipoprotein.
*Model I was adjusted for age and sex.
†Model II was adjusted for ankle/brachial index.only metabolic syndrome and high fasting glucose main-tained their predictive value, and low HDL approached
statistical significance. However, after adjustment for
ABI, which is a powerful marker of systemic atheroscle-
rosis,33 metabolic syndrome was the only factor to be
significantly associated with the presence of CAD.
CONCLUSION
This study first demonstrates that in PAD, metabolic
syndrome, which is present in 50% of the affected
individuals, is associated with low ABI, high levels of
CRP, and increased coexistence of CAD, which are all
significant predictors of cardiovascular events in
PAD.11,18,21 Therefore, our data should prompt future
prospective studies to assess whether in PAD the pres-
ence of metabolic syndrome adds clinically important
prognostic information to that provided by ABI and
CRP, and whether treating the most important causative
factor for the metabolic syndrome (ie, insulin resistance/
hyperinsulinemia)14,15 would be of value in reducing
cardiovascular risk. In this regard, it is noteworthy that
the newer insulin-sensitizing agents (ie, thiazolidinedio-
nes) improve glycemic control, reduce cardiovascular
risk factors, and generally result in a beneficial cardiovas-
cular disease profile.34-36
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